Feasibility Test of Folic Acid on Acute Kidney Injury

Launched by THE UNIVERSITY OF HONG KONG · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether folic acid, a common vitamin, can help adults who are suffering from acute kidney injury (AKI) while they are hospitalized. The main goal is to see if it’s possible to conduct a larger study in the future that tests how effective and safe folic acid supplementation is for managing AKI. Participants will be divided into three groups: one will receive standard hospital care, while the other two groups will get standard care plus either 1 mg or 5 mg of folic acid daily until their kidney condition improves, which could take up to 30 days.

To be eligible for this study, participants need to be adults aged 18 and older who are currently hospitalized with AKI and can give their consent to join. Those with certain health issues or who are pregnant, among other criteria, will not be able to participate. Throughout the trial, participants will be monitored closely while in the hospital and will have follow-up check-ins three months and one year after leaving the hospital to see how they are doing. This study is not yet recruiting participants, but it aims to gather important information that could help in treating kidney injuries in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients will be eligible for the study if ALL the following are present:
• • 1. Adults ≥18 years of age;
• • 2. AKI;
• • 3. Intended or existing hospitalisation;
• • 4. No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the study;
• • 5. Informed consent
• Exclusion Criteria:
• Patients will be excluded from the study if any of the following conditions is present:
• • 1. Refusal of consent expressed by the patient, close relative or legally appointed representative;
• • 2. Enrolled in other research studies within previous 30 days;
• • 3. Not expected to survive 3 days due to renal disease or other co-existing diseases;
• • 4. Planned inter-hospital transfer within 3 days;
• • 5. Recent surgery (\<30 days);
• • 6. Pregnancy;
• • 7. Cardiac arrest prior to inclusion;
• • 8. Contraindication to folate;
• • 9. Already on folate treatment